The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biomark Res
Main Authors: Wu, Yongfeng, Xu, Jinming, Xu, Jiawei, Wang, Yiqing, Wang, Luming, Lv, Wang, Hu, Jian
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2020
Assuntos:
Letter to the Editor
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/
https://ncbi.nlm.nih.gov/pubmed/32308981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares